Fwd: Drug Discovery@nature.com 20 November 2009

Advertisement TABLE OF CONTENTS 20 November 2009 News Analysis Research Highlights Research & Reviews Careers New from Clinical Pharmacology & Therapeutics: ClinPharmPod: Download and discover. Join us on clinpharmpod, CPT's own podcast, as we delve into cross-disciplinary advances in clinical pharmacology and experimental therapeutics. Clinpharmpod's first topic is emerging infections, with discussions on developing vaccines for emerging infections and the challenges related to protection of a vulnerable population.   News Top Fresh hope for German stem-cell patent case  doi:10.1038/462265a Referral to European Court may help to harmonize laws on intellectual property. Full Text Genzyme backs Osiris, despite Prochymal flop   doi:10.1038/nbt1109-966 Although three Phase III trials have failed, Osiris remains positive about its mesenchymal stem cell therapy. Full Text Efforts to improve vaccine stabilization heat up  doi:10.1038/nm1109-1232 Researchers are making progress in developing freeze protection technology for vaccines. Full Text Online resource aims to smooth the biomed patent search  doi:10.1038/nm1109-1242b A new online resource project aims to provide a free and multilayered global database of patented intellectual property in the life sciences. Full Text Nature Reviews Drug Discovery is now on Twitter. Follow us to keep up-to-date with the latest content. Analysis Top Restoring immunosuppression in RA doi:10.1038/scibx.2009.1618 Researchers have identified a way to dampen activation of T cells in rheumatoid arthritis and potentially other autoimmune diseases. Full Text Asenapine doi:10.1038/nrd3027 The US FDA has approved asenapine for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults. Full Text Influenza vaccine market dynamics doi:10.1038/nrd3026 Analysis of the challenges and long-term outlook of the influenza vaccine market. Full Text Research Highlights Top Metabolic disease: Dual benefit of bile acid receptor agonist doi:10.1038/nrd3032 An agonist of G protein-coupled bile acid receptor 1 is capable of both preventing weight gain and maintaining glucose homeostasis, revealing a possible new treatment for diabetes and obesity. Full Text HIV: A new starting point for HIV vaccine design doi:10.1038/nrd3035 Two new potent broadly neutralizing antibodies have been identified that shed light on a novel vaccine target. Full Text Mood disorders: Antidepressant action through gene regulation doi:10.1038/nrd3036 Inhibitors of histone deacetylases, enzymes that affect the acetylation status of histones and regulate the remodelling of chromatin, have antidepressant actions. Full Text Research & Reviews Top Can literature analysis identify innovation drivers in drug discovery?  doi:10.1038/nrd2973 This analysis reveals publication trends related to given disease areas and provides methods to monitor areas in which scientific advances are likely to create new therapeutic opportunities. Full Text New medicines to improve control and contribute to the eradication of malaria  doi:10.1038/nrd2972 Recent advances in genome-based technologies and in in vitro screening of whole parasites have broadened the range of therapeutic targets and are accelerating the development of a new generation of treatments for both malaria control and eradication. Full Text Development of universal antidotes to control aptamer activity doi:10.1038/nm.1990 A set of antidote molecules have been developed that are capable of counteracting the effects of an entire class of therapeutic agents based upon aptamers. Full Text In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses doi:10.1038/nbt.1564 Small interfering RNA synthetically linked to a CpG oligonucleotide agonist of toll-like receptor 9 targets and silences immunosuppressive genes and inhibits tumour growth in mouse models. Full Text Drug Discovery JOBS of the week Post Doctoral Research Worker in Molecular Neuroscience Institute of Psychiatry Denmark Hill, London Associate Professor Case Center for Proteomics and Bioinformatics Case Western Reserve University Cleveland, OH Drug discovery scientist SRG Oxfordshire, UK PhD Students in Molecular Medicine Centre for Molecular Medicine Norway NCMM, Oslo, Norway Oslo Norway More Science jobs from Drug Discovery EVENT 17th International Molecular Medicine Tri-Conference 03.-05.02.10 San Francisco, CA More science events from Careers Top Nanotechnology doi:10.1038/nrd3029 Our two interviewees this month discuss the multidisciplinary approach needed to translate nanotechnology-based therapies and products from the laboratory to the clinic. Full Text Top   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. More Nature Products More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.

--
SITBT